December 31, 2025 · Form 4 insider transaction
WALTERS GROUP bought 6,459,973 shares of Zentalis Pharmaceuticals, Inc. at $1.20 per share, a transaction worth $7.75M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 8 days after the transaction.
The shares of common stock reported herein (the "Shares") are held directly by The Walters Group (the "TWG"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose.